Tag:
AMR101
Latest Headlines
Latest Headlines
Amarin jumps on positive patent news for blockbuster hopeful
Amarin ( $AMRN ) eased some jitters over the strength of its IP protection for its lead drug AMR101 yesterday with the announcement of a notice of allowance for a U.S. patent for the formulation of its potential blockbuster cardiovascular disease drug.
FDA accepts Amarin's NDA for heart drug
Dublin-based Amarin ( $AMRN ) says the FDA has accepted the company's NDA for AMR101, a prescription omega-3 drug for the treatment of high triglycerides. Triglycerides are fats in the blood that can
Amarin seeks OK for new heart drug
Amarin has filed for an FDA approval of its fish-oil heart drug, AMR101. The small biotech hopes to win an approval to use the drug to treat patients with high levels of blood fat. And some analysts
Amarin to showcase data on blockbuster hopeful
Amarin ( $AMRN ) is gearing up to present data from its successful Phase III study of AMR101 for high triglyceride levels next week in Paris. It's another in a series of data presentations on potential
Amarin shares slide as investors fret over fate of AMR101 patent
Shares of Amarin ( $AMRN ) got roughed up yesterday after investors caught wind of the news that patent officials had issued a "final rejection" notice for a key filing on the biotech's experimental
Amarin sets stage for "aggressive" launch of omega 3 drug
Amarin is getting all its manufacturing ducks lined up in a row as it sets the stage to debut its experimental heart drug, AMR101. With positive data from two late-stage studies in hand to support
Amarin shares skyrocket as lead drug clears second Ph3
Shares of Amarin ( $AMRN ) doubled this morning after the developer announced a second round of upbeat Phase III data for its triglyceride drug, putting it on a path to a regulatory filing later this
Amarin's near-term potential prompts buyout interest
London's Amarin says interesting from potential buyers and partners has prompted the company to hire a financial adviser to review its strategic alternatives. The company has no approved products but
Amarin ($AMRN) shares soar on promising Ph3 triglyceride study
Flush with a promising set of late-stage data for the triglyceride-reducing AMR101, Amarin ( $AMRN ) plans to take a quick shortcut to the FDA, seeking an approval a full year ahead of schedule. The
